Biovica International AB (OSTO:BIOVIC B) ROCE % : -94.55% (As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Biovica International AB ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Biovica International AB's annualized ROCE % for the quarter that ended in Jan. 2024 was -94.55%.

Biovica International AB ROCE % Historical Data

The historical data trend for Biovica International AB's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biovica International AB ROCE % Chart

Biovica International AB Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

ROCE %

Get a 7-Day Free Trial

-33.80

-44.42

-29.65

-37.54

-77.89

Biovica International AB Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
ROCE %	Get a 7-Day Free Trial															-85.64	-89.33	-96.02	-90.94	-94.55

Biovica International AB ROCE % Calculation

Biovica International AB's annualized ROCE % for the fiscal year that ended in Apr. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Apr. 2023 )		(A: Apr. 2022 )		(A: Apr. 2023 )
	=	-110.68	/	( ( (151.631 - 16.094)	+	(172.288 - 23.638) )	/ 2 )
	=	-110.68	/	( (135.537	+	148.65)	/ 2 )
	=	-110.68	/	142.0935
	=	-77.89 %

Biovica International AB's ROCE % of for the quarter that ended in Jan. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jan. 2024 )		(Q: Oct. 2023 )		(Q: Jan. 2024 )
	=	-109.668	/	( ( (104.222 - 15.016)	+	(158.32 - 15.535) )	/ 2 )
	=	-109.668	/	( ( 89.206	+	142.785 )	/ 2 )
	=	-109.668	/	115.9955
	=	-94.55 %

(1) Note: The EBIT data used here is four times the quarterly (Jan. 2024) EBIT data.

Biovica International AB (OSTO:BIOVIC B) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Biovica International AB ROCE % Related Terms

Thank you for viewing the detailed overview of Biovica International AB's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Biovica International AB (OSTO:BIOVIC B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biovica International AB (OSTO:BIOVIC B) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

9II:Germany

Address

Dag Hammarskjolds vag 54B, Uppsala Science Park, Uppsala, SWE, 752 37

Website

http://www.biovica.com

Biovica International AB is a biotech company. It develops and commercializes blood-based diagnostic tests with biomarkers that improve monitoring and evaluation of modern cancer treatments. Through collaboration with world- leading cancer institutes and pharmaceutical companies, it promotes the trend in healthcare for personalized treatment, with a primary focus on patient survival and benefits to society. DiviTum is manufactured by the company and sold as a kit consisting of a reaction plate with reagents that have been optimized for ELISA applications.

Biovica International AB (OSTO:BIOVIC B) Headlines

No Headlines